17.10.2012 • NewsAbbottQ3 2012pharmaceutical industry

Abbott Q3 Profit Tops View

Abbott Laboratories reported mixed quarterly results, with earnings topping estimates but sales missing expectations as growth slowed for its Humira arthritis drug and other branded medicines and for its nutritional products.

Abbott said on Wednesday it earned $1.94 billion, or $1.21 per share, in the third quarter, compared with $303 million, or 19 cents per share, in the year-earlier period, when the company took a $1.4 billion litigation-related charge.

Excluding special items, Abbott earned $1.30 per share. Analysts, on average, expected $1.28, according to Thomson Reuters I/B/E/S.

Global sales fell 0.4% to $9.77 billion and fell short of Wall Street expectations of $9.93 billion. Sales would have risen 4.1%, if not for a stronger dollar, which lowers the value of sales in overseas markets.

Abbott said it remains on track to spin off its branded drugs business by Jan. 1, 2013 into a publicly traded company called AbbVie.

Abbott narrowed its full-year 2012 profit forecast to $5.06 to $5.08 per share, from an earlier outlook of $5.00 to $5.10.

Sales of Humira, by far its biggest product, rose 10.1% to $2.33 billion - a slowdown from growth of almost 17% in the prior quarter.

Revenue from Abbott's array of patent-protected prescription drugs, which it calls proprietary pharmaceuticals, rose 2.4% to $4.42 billion, while sales of nutritional products rose 4.5% to $1.6 billion. Growth in both categories slowed down from the second quarter.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.